| Authors: |
DeFilipp Z; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA., Choe H; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Efebera YA; Division of Hematology, Department of Blood and Marrow Transplant, OhioHealth, The Ohio State University, Columbus, OH., Saad A; Division of Acute Leukemia, College of Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia., Farhan S; Division of Hematology Oncology, Department of Internal Medicine, Henry Ford Health, Detroit, MI., Lekakis L; Division of Transplantation and Cellular Therapy, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL., Yared JA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD., Schiller G; Division of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, CA., Mapara MY; Division of Hematology/Oncology, Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, NY., Assal A; Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY., Gooley T; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Bui JD; Department of Pathology, University of California San Diego, La Jolla, CA., Lee D; Department of Clinical Development, REGiMMUNE Corporation, Tokyo, Japan., Lane H; Department of Clinical Development, REGiMMUNE Corporation, Tokyo, Japan., Chen YB; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA. |
